

CLAIMS

- 1) A crystallisation process comprising:
- 5 a) dissolving the substance to be crystallised in a medium wherein the viscosity of the medium can be adjusted;
- 10 b) applying a means for adjusting the viscosity of the medium until a gel with an apparent viscosity in the range 25 to 90 Pa.s at a shear rate of  $1\text{s}^{-1}$  is reached;
- c) allowing crystal growth;
- 15 d) applying a means for adjusting the viscosity of the medium until a fluid with an apparent viscosity less than 25 Pa.s at a shear rate of  $1\text{s}^{-1}$  is reached; and
- e) harvesting the crystals.
- 20 2) A crystallisation process as claimed in claim 1, wherein the means for adjusting the viscosity of the medium is temperature change, ultrasound, thixotropicity, electro-rheology, mechanical shear, chemical additive, or pH change.
- 25 3) A crystallisation process as claimed in claim 2 wherein the means for adjusting the viscosity of the medium is pH change.
- 4) A crystallisation process as claimed in <sup>2</sup>~~any preceding claim~~ <sup>Claim 1</sup> wherein the medium is an aqueous solution of a Carbomer.
- 30 5) A crystallisation process as claimed in claim 4, wherein the Carbomer is Carbopol 934<sup>TM</sup>.
- (112)

- (6) A crystallisation process as claimed in ~~any preceding claim~~ wherein the substance to be crystallised is a drug substance or a carrier for drug particles, suitable for use in an inhaled pharmaceutical composition. *claim 1*
- 5 7) A crystallisation process as claimed in ~~any preceding claim~~ wherein the substance to be crystallised is lactose, lactose monohydrate, salbutamol sulphate or ipratropium bromide. *claim 1*
- 10 8) A crystallisation process as claimed in ~~any preceding claim~~, wherein the crystals are harvested by means of collection by filtration. *claim 1*
- 9) A crystallisation process as claimed in ~~any preceding claim~~, wherein the process comprises: *claim 1*
- 15 a) dissolving the substance to be crystallised in an aqueous solution of a medium wherein the viscosity of the medium is pH-dependent;
- 20 b) adjusting the pH of the medium until a gel with an apparent viscosity in the range 25 to 90 Pa.s at a shear rate of  $1\text{s}^{-1}$  is reached;
- 25 c) allowing crystal growth;
- d) adjusting the pH of the medium until a fluid with an apparent viscosity less than 25 Pa.s at a shear rate of  $1\text{s}^{-1}$  is reached; and
- e) harvesting the crystals.
- 30 10) A process as claimed in claim 9 wherein the medium is an aqueous solution of a Carbomer.
- (11) A crystallisation process as claimed in ~~claim 1 or 2~~ wherein the substance to be crystallised is fluticasone propionate or salmeterol xinafoate

- 12) Lactose monohydrate crystals obtained according to the process as claimed in ~~any preceding claim.~~ *claim 1*
- 5 13) Lactose monohydrate crystals as claimed in claim 12 for use in powder formulations for inhaled use.
- 10 14) Salbutamol sulphate, oxitropium bromide or ipratropium bromide crystals obtained according to the process as claimed in ~~any of claims 1 to 10.~~ *claim 1*
- 15 15) Fluticasone propionate or salmeterol xinafoate crystals obtained according to the process as claimed in claim 1 ~~or 2.~~
- 16) Salbutamol sulphate, oxitropium bromide or ipratropium bromide crystals as claimed in claim 14 for use in powder formulations for inhaled use.
- 17) Fluticasone propionate or salmeterol xinafoate crystals as claimed in claim 15 for use in powder formulations for inhaled use.
- 18) A pharmaceutical formulation for administration by inhalation comprising lactose monohydrate crystals as claimed in claim 12 and/or salbutamol sulphate or ipratropium bromide crystals ~~as claimed in claim 14.~~
- 19  
18) A pharmaceutical formulation for administration by inhalation comprising lactose monohydrate crystals as claimed in claim 12 and/or fluticasone propionate or salmeterol xinafoate crystals ~~as claimed in claim 15.~~

*Rule 126*

*add B1*

*add C1*

*add D1*